Consistent with our results, Hou et al. who conducted a study to explore the role of Claudin-7, a p53 regulated gene, in tumorigenesis and progression of CRC through quantitative real-time PCR, Western blot, a luciferase reporter assay, and immunohistochemistry, found no correlation between clinicopathological parameters (tumor size, invasion depth, lymphatic metastasis, stage III/IV) and Claudin-7 high expression. The gene discussed is CLDN7; the disease is neoplasm.